Skip to content


BMC Proceedings

Open Access

TGF-β polymorphism and its expression correlated with CXCR4 expression in human breast cancer

  • Julie Massayo Maeda Oda1Email author,
  • Karen Brajão de Oliveira1,
  • Roberta Losi Guembarovski1,
  • Alda Losi Guembarovski2,
  • Glauco Akelinghton Freire Vitiello1,
  • Patricia Midori Murobushi Ozawa1,
  • Bruna Karina Banin Hirata1,
  • Vânia Darc de Castro1 and
  • Maria Angelica Ehara Watanabe1
BMC Proceedings20137(Suppl 2):P38

Published: 4 April 2013


It is known that the transforming growth factor beta (TGF-β) can act as both a tumor suppressor and as a significant stimulator of tumor progression, invasion, and metastasis. It has been suggested a link between TGF-β and CXCR4 expression in human breast cancer cells, which may be one of the mechanisms of TGF-β mediated enhancement of metastatic potential in breast cancer cells. Therefore, the objective of the present study was to investigate the TGF-β T869C polymorphism and its expression correlated with CXCR4 expression in breast cancer patients.

Patients and methods

Genomic DNA was obtained from 21 samples of peripheral blood or from normal tissue previously fixed in formalin and embedded in paraffin for TGF-β T869C polymorphism analyses. Total cellular RNA was extracted from the same 21 patients, but from fresh tissue (tumor and adjacent healthy from the same breast) to expression analysis by Real Time PCR.


No significant differences were observed in genotype distribution according to clinic pathological characteristics. TGF-β mRNA expression was assessed according to T869C polymorphism and CC patients presented a higher TGF-β expression but not significant when compared to other genotypes (p=0.064). A positive correlation was observed in relative mRNA expressions of CXCR4 and TGF-β (p= 0.020). It is known that overexpression of TGF-β by both tumor and stromal tissue can facilitate the development of metastases, mainly by TGF-β stimulated angiogenesis and increased tumor cell motility.


Our findings suggested a role of these genes as progression markers for breast carcinoma.

Financial support

CNPq, CAPES, Fundação Araucaria and PROPPG-UEL.

Authors’ Affiliations

Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina, Brazil
Laboratory of Pathology, Healthy Sciences Center, State University of Londrina and Laboratory of Applied Pathology, MICROPAR, Londrina, Brazil


© Oda et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.